DVLA eye conditions warning as drivers could face £1,000 fine
Motorists risk being hit with an eye-watering £1,000 fine if they fail to declare certain conditions to the DVLA ...
thecardiologyadvisor.com22h
Continuous Glucose Monitoring Can Predict Microvascular Complications in Type 1 Diabetes
Fourteen-day continuous glucose monitoring (CGM) traces added to Diabetes Control and Complications Trial (DCCT) data can predict microvascular diabetes complications similarly to glycated hemoglobin.
New Atlas1d
Ozempic is suspected in more cases of sudden vision loss
Scientists remain puzzled as to why some individuals taking popular weight loss and diabetes medications such as Ozempic and ...
Endocrinology Advisor1d
Susvimo Approval Expanded to Include Diabetic Macular Edema
The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.
devdiscourse1d
AI steps up in the battle against diabetes complications
AI has demonstrated considerable potential in diabetic foot (DF) management. AI-powered thermal imaging and predictive ...
EyePoint stock jumps 10% on Duravyu study results
EyePoint (EYPT) stock rose 10% after the company reported six-month results from a phase 2 study of its drug Duravyu in the treatment of diabetic macular edema. Read more here.
'Good' cholesterol might not be so good for glaucoma
The cholesterol that's good for your heart health might be bad for your eye health and vice versa, a new study says.
'Good' cholesterol may be linked to heightened glaucoma risk among over 55s
"Good" (HDL) cholesterol, usually considered to be beneficial for health, may be linked to a heightened risk of the serious ...
With FDA approval, Genentech turns eye implant's focus to diabetes
Genentech Inc. won regulatory approval Tuesday to market an eye implant that can be refilled every six months with an already ...
Business Wire2d
FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...
Researchers probe potential role of Ozempic, other weight-loss drugs in vision loss
Physician–scientists at the University of Utah's John A. Moran Eye Center have published an investigatory review of nine patients who experienced vision complications while taking popular semaglutide ...